Shareholder Alert for Hims & Hers Health, Inc. (HIMS)

0Likes

98Views

Jul 312025

Anyone who incurred a loss as a result of this misconduct can join the suit: https://zlk.com/pslra-1/hims-hers-hea... Hims said it could help people lose weight—but all that got lighter were investors’ wallets. The telehealth giant launched a weight-loss drug program in partnership with Novo Nordisk. But behind the scenes, Hims relied on a third-party compounding pharmacy that sourced ingredients from an unapproved Chinese supplier. When investors found out, Him stock plunged thirty-four percent. Now, investors are suing. In April twenty twenty-five, Hims bragged about a new collab with Novo Nordisk. Novo promised Hims a legitimate way to distribute Weygovy. This looked to be a huge win for Hims, with execs claiming the “legit” GLP-1 program could drive profits. But behind the scenes, the program included GLP-1s compounded using ingredients from a Chinese-based supplier not authorized by Novo. In June, Novo cut ties. Hims stock dropped 34% as investors realized the “legit” launch might not have been so clean after all. Now, shareholders are suing, saying they were misled.rules. Hims’ legit GLP-1 wasn’t so legit after all, as it was procured from Chinese generics. Investors bailed, and Hims stock crashed. Now, more shareholders are joining the lawsuit.